AUTHORS
Giuseppe Gaetano Loscocco, MD, PhD, Manjola Balliu, PhD2, Niccolò Bartalucci, PhD3, Sebastiano Rontauroli, PhD4, Alessio Enderti, MSC5, Lara Tavernari6, Raffaella Santi7, Valentina Boldrini8, Carmela Basile9, Giulio Capecchi10, Ruggiero Norfo11, Cecilia Matteoli12, Chiara Paoli, PhD13, Rossella Manfredini, PhD, BSc14, Paola Guglielmelli, MD, PhD15, Alessandro Vannucchi, MD16
AFFILIATIONS
1 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
3 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
4 Interdepartmental Centre for Stem Cells and Regenerative Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
5 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
6 Interdepartmental Centre for Stem Cells and Regenerative Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
7 Department of Health Sciences, Pathology Section, University of Florence, Florence, Italy
8 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
9 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
10 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
11 Interdepartmental Centre for Stem Cells and Regenerative Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
12 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
13 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
14 Interdepartmental Centre for Stem Cells and Regenerative Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
15 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
16 Department of Experimental and Clinical Medicine, University of Florence, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Florence, Italy
ABSTRACT
Background: Myelofibrosis (MF) is driven by aberrant JAK-STAT signaling and a profibrotic/proangiogenic bone marrow (BM) niche. JAK inhibitors (JAKi) improve spleen volume (SV) and symptoms in patients with MF, but responses may be partial or short-lived, and cytopenias can limit treatment. Nintedanib (NIN), FDA-approved for pulmonary fibrosis, inhibits PDGFR, FGFR and VEGFR, known mediators of stromal activation, angiogenesis and extracellular matrix remodeling. Whether combined JAK-STAT and stromal-directed inhibition can improve disease control after suboptimal JAKi response is unknown.
Index case: A patient with post-polycythemia vera MF received ruxolitinib (RUX) 15 mg twice daily. After 24 weeks, hemoglobin decreased from 10.1 to 9.2 g/dL, platelets from 235 to 121×109/L, erythropoietin (EPO) increased from 22.7 to 200 IU/L, LDH was 435 U/L, and SV increased from 1063 to 1269 cm3, while MFSAF TSS improved from 45 to 25, consistent with suboptimal response. NIN 150 mg twice daily was prescribed concurrently for worsening pre-existing idiopathic pulmonary fibrosis; RUX was continued unchanged. At 6 weeks, hemoglobin increased from 9.2 to 10.3 g/dL, platelets from 121 to 146×109/L; imaging at 12 weeks showed SV reduction from 1269 to 895 cm3 (-29.5%). After nearly 3 years at unchanged doses, hemoglobin increased to 13.8 g/dL (+50% from week 24), platelets to 219×109/L (+81%), LDH decreased to 301 U/L (-31%), EPO to 27 IU/L (-86.5%), SV to 361 cm3 (-71.6%), liver volume to 2199 cm3 (-26.9%); MFSAF TSS further decreased to 9 (-80% vs baseline). The combination was well tolerated, without interruptions or toxicity requiring dose modification. BM histopathology at 150 weeks of NIN+RUX showed decreased reticulin fibrosis from MF-3 to MF-1, reduced collagen deposition, osteosclerosis and megakaryocyte (Mk) clustering. JAK2V617F VAF was 97.0% at RUX start, 97.6% after 24 weeks of RUX, and 55% after 24 weeks of NIN+RUX.
Methods: Prompted by this observation, we investigated its biological basis. Longitudinal colony-forming assays used patient-derived CD34+ cells; paired transcriptomic profiling was performed in granulocytes at baseline, during RUX, and during NIN+RUX. Parental and RUX-, fedratinib (FED)- or momelotinib (MOM)-resistant JAK2V617F-mutated SET-2 and HEL cells were treated with NIN alone or combined with JAKi. Growth was assessed by WST-1 at 48 hours and combination index (CI) by Chou-Talalay. In a romiplostim-induced MF-like model (100 µg/kg s.c. twice weekly for 2 weeks; Bianchi et al., Leukemia, 2023), C57BL/6J mice (n=4-5/group) received vehicle, NIN 60 mg/kg, RUX 30 mg/kg or NIN+RUX daily and were sacrificed on day 15.
Results: After 24 weeks of NIN+RUX, CD34+ cell colony assays showed significantly increased CFU-GEMM, BFU-E and CFU-Mk and reduced CFU-GM versus baseline; colony genotyping is ongoing. Granulocyte transcriptomics identified a distinct NIN+RUX profile versus baseline and RUX alone, with significant downregulation of inflammatory response, TNFα/NF-κB, angiogenesis and hypoxia programs. NIN inhibited growth in parental and JAKi-resistant cell lines (IC50 range, 1.74-7.06 µM). Across 12 settings, NIN synergized with RUX, FED and MOM (CI range, 0.218-0.803), with lower residual growth than either single agent throughout. In romiplostim-treated mice, the monotherapies showed distinct effects: RUX reduced spleen weight by 36.6% (p=0.001), whereas NIN reduced histologic Mk counts by 39.4% (p=0.001). Both agents increased erythroid cells, by 61.1% with NIN (p=0.029) and 92.5% with RUX (p=0.002). NIN+RUX reduced spleen weight by 44.2% and histologic Mk counts by 31.7%, increased erythroid cells by 69.0% (all p≤0.028), and attenuated BM fibrosis. Importantly, NIN+RUX was the only treatment to significantly reduce both thrombocytosis (-40.8%; p=0.002) and marrow Mk progenitors (-40.5%; p=0.006) versus romiplostim controls; Mk progenitors were also significantly lower than with either NIN (p=0.001) or RUX (p=0.008) alone.
Conclusions: Incidental findings in an index case, strengthened by in vitro and in vivo models, support dual targeting of JAK-STAT and profibrotic/angiogenic growth factor signaling in MF. NIN alone showed activity in JAKi-resistant models and synergized with three JAKi. These findings provide the mechanistic and translational foundation for prospective phase II evaluation of NIN added to RUX in MF pts with suboptimal response, resistance, or loss of response to JAK inhibition.
DISCLOSURES
Giuseppe Gaetano Loscocco, MD, PhD: AOP Health - Honoraria; AOP, GSK, Novartis - Honoraria; Novartis - Honoraria; GSK - Honoraria; GSK - Consultancy (Includes expert testimony)